{"id":"sipv-bopv-bopv-vaccination-schedule","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing inactivated poliovirus and rotavirus antigens to the body, which triggers an immune response and helps to prevent future infections.","oneSentence":"The sIPV-bOPV-bOPV vaccine stimulates the body's immune system to produce antibodies against poliovirus and rotavirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:05.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis and rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"sIPV-bOPV-bOPV vaccination schedule","genericName":"sIPV-bOPV-bOPV vaccination schedule","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"The sIPV-bOPV-bOPV vaccine stimulates the body's immune system to produce antibodies against poliovirus and rotavirus. Used for Prevention of poliomyelitis and rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}